At Verified Market Intelligence, we provide a market study that encompasses both qualitative and quantitative assessments of latest trends for the market segmentations classified by our analysts. According to Verified Market Intelligence, the Global Pemetrexed Diacid Market was valued at USD 3.83 billion in 2017 and is projected to reach USD 6.41 billion by 2025, growing at a CAGR of 6.7% from 2018 to 2025.
With growing pre-disposition towards cancer, people are more alert and looking for solutions that can help cure cancer. Pemetrexed diacid is one such drug approved by the Food and Drug Administration (FDA) to be used in the treatment of cancer in chemotherapy and immunotherapy. It can be used as a supplement or in combination therapy with carboplatin or cisplatin. This drug flourished the pharmaceutical and healthcare industry.
The Global Pemetrexed Diacid Market is segmented on the basis of consumption type, cancer type, therapeutic modalities and geography. Increased reported cases of lung cancer and growing consumption of chemotherapy has accelerated the global pemetrexed diacid market. Apart from this, Production of generics due to loss of patent might hamper the overall growth rate.
The "Global Pemetrexed Diacid Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Eli Lilly and Company, Fresenius KABI, Teva Pharmaceutical Industries Ltd., Dr Reddy's Laboratories, Abbott Laboratories, Cadila Healthcare Ltd, Accord Healthcare Inc, QILU Pharma Co Ltd, Accure Labs Pvt. Ltd, Pfizer Inc. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
As a part of market estimation, the study also comprises a list of tables and figures for the "Global Pemetrexed Diacid Market" which focuses on a constructive knowledge essential for the companies or individuals interested in the market study report. As a part of market segmentation, our study exhibits a market analysis on the basis of type, industry application and geography.
On the basis of type, the Global Pemetrexed Diacid Market can be categorized into three sections; by consumption type, cancer type and therapeutic modality. This market study analyses the industry for Global Pemetrexed Diacid Market based on these divisions. Pemetrexed Diacid Market consumption is divided into supplements and cancer type. The industry is then sectioned by cancer type which includes lung cancer, liver cancer, colorectal cancer, stomach cancer, breast cancer and others. In terms of geography, Asia Pacific accounts for the fastest growing market due to the presence of numerous developing countries in this region along with their emerging markets. The Chinese market has a major share in this region.
Chapter 1 INTRODUCTION OF GLOBAL PEMETREXED DIACID MARKET 14
1.1 Market Overview 14
1.2 Market Segmentation 15
1.3 Assumptions 16
Chapter 2 EXECUTIVE SUMMARY 17
2.1 Overview of the Market 17
2.2 Global Pemetrexed Diacid Market, By Consumption Type (USD Million) 18
2.3 Global Pemetrexed Diacid Market, By Cancer Type (USD Million) 19
2.4 Global Pemetrexed Diacid Market Shares, By Therapeutic Modalities, 2016 (%) 20
2.5 Global Pemetrexed Acid Market, By Geography (USD Million) 21
Chapter 3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE 22
3.1 Data Mining 22
3.2 Secondary Research 22
3.3 Primary Research: 22
3.4 Subject Matter Expert Advice: 23
3.5 Quality Check 23
3.6 Final Review 23
3.7 Validation 24
3.8 Primary Interviews 24
3.9 Research Scope and Assumptions 24
3.10 List of data sources 25
Chapter 4 GLOBAL PEMETREXED DIACID MARKET OUTLOOK 26
4.1 Market Dynamics 26
4.1.1 Market Drivers 27
4.1.1.1 Rising Instances of lung cancer 27
4.1.1.2 Increasing consumption of chemotherapy drugs in developing countries 28
4.1.2 Market Restraints 29
4.1.2.1 High cost of chemotherapy drug development 29
4.1.2.2 Effects of pemetrexed diacid 30
4.1.3 Market Challenges 31
4.1.3.1 Loss of patent exclusivities giving rise to generics 31
4.2 Porter's Five Force Analysis 32
Chapter 5 GLOBAL PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE 33
5.1 Overview 34
5.2 In Combination with Cisplatin/Carboplatin 35
5.3 Supplement 36
Chapter 6 GLOBAL PEMETREXED DIACID MARKET, BY CANCER TYPE 38
6.1 Overview 39
6.2 Lung Cancer 41
6.3 Liver Cancer 42
6.4 Colorectal Cancer 43
6.5 Stomach 44
6.6 Breast 45
6.7 Others 46
Chapter 7 GLOBAL PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY 47
7.1 Overview 48
7.2 Chemotherapy 50
7.3 Immunotherapy 51
7.4 Other 52
Chapter 8 GLOBAL PEMETREXED DIACID MARKET, BY GEOGRAPHY 53
8.1 Overview 54
8.2 North America 57
8.2.1 U.S. 61
8.2.2 Canada 64
8.2.3 Mexico 67
8.3 Europe 70
8.3.1 Germany 75
8.3.2 UK 78
8.3.3 France 81
8.4 Asia Pacific 84
8.4.1 China 88
8.4.2 Japan 91
8.4.3 India 94
8.5 Latin America 97
8.5.1 Brazil 101
8.6 Rest Of the World 104
Chapter 9 Competitive Landscape 107
Chapter 10 COMPANY PROFILES 111
10.1 Eli Lilly and Company 111
10.1.1 Company Overview 111
10.1.2 Eli Lilly and Company: Key Facts 111
10.1.3 Financial Performance 112
10.1.4 Product Benchmarking 113
10.1.5 Eli Lilly and Company: SWOT Analysis 114
10.2 Fresenius KABI 115
10.2.1 Company Overview 115
10.2.2 Fresenius KABI: Key Facts 115
10.2.3 Financial Performance 116
10.2.4 Product Benchmarking 117
10.2.5 Fresenius KABI: SWOT Analysis 118
10.3 Teva Pharmaceutical Industries Ltd. 119
10.3.1 Company Overview 119
10.3.2 Teva Pharmaceutical Industries Ltd.: Key Facts 119
10.3.3 Financial Performance 120
10.3.4 Product Benchmarking 121
10.3.5 Teva Pharmaceutical Industries Ltd.: SWOT Analysis 122
10.4 Dr Reddy's Laboratories 123
10.4.1 Company Overview 123
10.4.2 Dr Reddy's Laboratories: Key Facts 123
10.4.3 Financial Performance 124
10.4.4 Product Benchmarking 125
10.4.5 Dr. Reddy's Laboratories: SWOT Analysis 126
10.5 Abbott Laboratories 127
10.5.1 Company Overview 127
10.5.2 Abbott Laboratories: Key Facts 127
10.5.3 Financial Performance 128
10.5.4 Product Benchmarking 128
10.5.5 Abbott Laboratories: SWOT Analysis 129
10.6 Cadila Healthcare Ltd 130
10.6.1 Company Overview 130
10.6.2 Cadila Healthcare: Key Facts 130
10.6.3 Financial Performance 131
10.6.4 Product Benchmarking 131
10.7 Accord Healthcare Inc. 132
10.7.1 Company overview 132
10.7.2 Accord Healthcare Inc.: Key Facts 132
10.7.3 Financial Performance (Intas Pharmaceuticals Ltd.) 133
10.7.4 Product Benchmarking 133
10.8 QILU Pharma Co Ltd. 134
10.8.1 Company Overview 134
10.8.2 QILU Pharma Co Ltd: Key Facts 134
10.8.3 Product Benchmarking 134
10.9 Accure Labs Pvt. Ltd 135
10.9.1 Company Overview 135
10.9.2 Accure Labs Pvt. Ltd: Key Facts 135
10.9.3 Product Benchmarking 135
10.10 Pfizer Inc. 136
10.10.1 Company Overview 136
10.10.2 Pfiser Inc :Key Facts 136
10.10.3 Financial Performance 137
10.10.4 Product Benchmarking 138
List of Tables
TABLE 1 GLOBAL PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 35
TABLE 2 GLOBAL PEMETRXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 40
TABLE 3 GLOBAL PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 49
TABLE 4 GLOBAL PEMETREXED DIACID MARKET, BY GEOGRAPHY, 2012 - 2025 (USD MILLION) 56
TABLE 5 NORTH AMERICA PEMETREXED DIACID MARKET, BY COUNTRY, 2012 - 2025 (USD MILLION) 58
TABLE 6 NORTH AMERICA PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 59
TABLE 7 NORTH AMERICA PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 59
TABLE 8 NORTH AMERICA PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 60
TABLE 9 U.S. PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 61
TABLE 10 U.S. PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 62
TABLE 11 U.S. PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 62
TABLE 12 CANADA PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 64
TABLE 13 CANADA PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 65
TABLE 14 CANADA PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 65
TABLE 15 MEXICO PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 67
TABLE 16 MEXICO PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 68
TABLE 17 MEXICO PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 68
TABLE 18 EUROPE PEMETREXED DIACID MARKET, BY COUNTRY, 2012 - 2025 (USD MILLION) 71
TABLE 19 EUROPE PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 72
TABLE 20 EUROPE PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 73
TABLE 21 EUROPE PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 73
TABLE 22 GERMANY PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 75
TABLE 23 GERMANY PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 76
TABLE 24 GERMANY PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 76
TABLE 25 UK PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 78
TABLE 26 UK PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 79
TABLE 27 UK PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 79
TABLE 28 FRANCE PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 81
TABLE 29 FRANCE PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 82
TABLE 30 FRANCE PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 82
TABLE 31 ASIA PACIFIC PEMETREXED DIACID MARKET, BY COUNTRY, 2012 - 2025 (USD MILLION) 85
TABLE 32 ASIA PACIFIC PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 86
TABLE 33 ASIA PACIFIC PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 86
TABLE 34 ASIA PACIFIC PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 87
TABLE 35 CHINA PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 88
TABLE 36 CHINA PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 89
TABLE 37 CHINA PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 89
TABLE 38 JAPAN PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 91
TABLE 39 JAPAN PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 92
TABLE 40 JAPAN PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 92
TABLE 41 INDIA PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 94
TABLE 42 INDIA PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 95
TABLE 43 INDIA PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 95
TABLE 44 LATIN AMERICA PEMETREXED DIACID MARKET, BY COUNTRY, 2012 - 2025 (USD MILLION) 98
TABLE 45 LATIN AMERICA PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 99
TABLE 46 LATIN AMERICA PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 99
TABLE 47 LATIN AMERICA PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 100
TABLE 48 BRAZIL PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 101
TABLE 49 BRAZIL PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 102
TABLE 50 BRAZIL PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 102
TABLE 51 REST OF WORLD PEMETREXED DIACID MARKET, BY CONSUMPTION TYPE, 2012 - 2025 (USD MILLION) 104
TABLE 52 REST OF WORLD PEMETREXED DIACID MARKET, BY CANCER TYPE, 2012 - 2025 (USD MILLION) 105
TABLE 53 REST OF WORLD PEMETREXED DIACID MARKET, BY THERAPEUTIC MODALITY, 2012 - 2025 (USD MILLION) 105
TABLE 54 LIST OF ALL MANUFACTURERS & SUPPLIERS OF PEMETREXED LICENSING 107
List of Figures
FIG. 1 GLOBAL PEMETREXED DIACID MARKET SEGMENTATION 15
FIG. 2 GLOBAL PEMETREXED DIACID MARKET OUTLOOK 26
FIG. 3 LUNG AND BRONCHUS CANCER IN U.S. (NUMBER OF NEW CASES AND DEATHS PER 100,000 PEOPLE (ALL RACES, MALES AND FEMALES), AGE-ADJUSTED) 27
FIG. 4 GLOBAL PEMETREXED DIACID MARKET SHARE, BY CONSUMPTION TYPE, 2016 (%) 34
FIG. 5 GLOBAL PEMETREXED DIACID MARKET REVENUE ON CONSUMPTION WITH CISPLATIN/CARBOPLATIN, 2012 - 2025 (USD MILLION) 36
FIG. 6 GLOBAL PEMETREXED DIACID MARKET REVENUE ON CONSUMPTION AS SUPPLEMENT, 2012 - 2025 (USD MILLION) 37
FIG. 7 GLOBAL PEMETREXED DIACID MARKET SHARE, BY CANCER TYPE 39
FIG. 8 GLOBAL PEMETREXED DIACID MARKET DEMAND IN LUNG CANCER, 2012 - 2025 (USD MILLION) 41
FIG. 9 GLOBAL PEMETREXED DIACID MARKET DEMAND IN LIVER CANCER, 2012 - 2025 (USD MILLION) 42
FIG. 10 GLOBAL PEMETREXED DIACID MARKET DEMAND IN COLORECTAL CANCER, 2012 - 2025 (USD MILLION) 43
FIG. 11 GLOBAL PEMETREXED DIACID MARKET DEMAND IN STOMACH CANCER, 2012 - 2025 (USD MILLION) 44
FIG. 12 GLOBAL PEMETREXED DIACID MARKET DEMAND IN BREAST CANCER, 2012 - 2025 (USD MILLION) 45
FIG. 13 GLOBAL PEMETREXED DIACID MARKET DEMAND IN OTHER CANCER TYPES, 2012 - 2025 (USD MILLION) 46
FIG. 14 GLOBAL PEMETREXED DIACID MARKET SHARE, BY THERAPEUTIC MODALITY, 2016 (%) 48
FIG. 15 GLOBAL PEMETREXED DIACID MARKET DEMAND IN CHEMOTHERAPY, 2012 - 2025 (USD MILLION) 50
FIG. 16 GLOBAL PEMETREXED DIACID MARKET DEMAND IN IMMUNOTHERAPY, 2012 - 2025 (USD MILLION) 51
FIG. 17 GLOBAL PEMETREXED DIACID MARKET DEMAND IN OTHER THERAPEUTIC MODALITIES, 2012 - 2025 (USD MILLION) 52
FIG. 18 GLOBAL PEMETREXED DIACID MARKET, BY GEOGRAPHY, 2012 - 2025 55
FIG. 19 NORTH AMERICA MARKET SNAPSHOT 57
FIG. 20 NORTH AMERICA PEMETREXED DIACID MARKET, BY COUNTRY, 2016 58
FIG. 21 U.S. PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 61
FIG. 22 CANADA PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 64
FIG. 23 MEXICO PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 67
FIG. 24 EUROPE MARKET SNAPSHOT 70
FIG. 25 EUROPE PEMETREXED DIACID MARKET, BY COUNTRY, 2016 71
FIG. 26 GERMANY PEMETREXED DIACID, 2012 - 2025 (USD MILLION) 75
FIG. 27 UK PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 78
FIG. 28 FRANCE PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 81
FIG. 29 ASIA PACIFIC MARKET SNAPSHOT 84
FIG. 30 ASIA PACIFIC PEMETREXED DIACID MARKET, BY COUNTRY, 2016 85
FIG. 31 CHINA PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 88
FIG. 32 JAPAN PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 91
FIG. 33 INDIA PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 94
FIG. 34 LATIN AMERICA PEMETREXED DIACID MARKET, BY COUNTRY, 2016 98
FIG. 35 BRAZIL PEMETREXED DIACID MARKET, 2012 - 2025 (USD MILLION) 101
FIG. 36 REST OF WORLD OPERATION ANALYTICS MARKET, 2012 - 2025 (USD MILLION) 104
FIG. 37 ELI LILLY AND COMPANY FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION) 112
FIG. 38 ELI LILLY AND COMPANY FINANCIAL PERFORMANCE, BY REGION (% REVENUE, 2016) 113
FIG. 39 ELI LILLY AND COMPANY: SWOT ANALYSIS 114
FIG. 40 FRESENIUS KABI FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION) 116
FIG. 41 FRESENIUS KABI FINANCIAL PERFORMANCE, BY REGION (% REVENUE, 2016) 117
FIG. 42 FRESENIUS KABI: SWOT ANALYSIS 118
FIG. 43 TEVA PHARMACEUTICAL INDUSTRIES LTD. FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION) 120
FIG. 44 TEVA PHARMACEUTICAL INDUSTRIES LTD. FINANCIAL PERFORMANCE, BY REGION (% REVENUE, 2016) 121
FIG. 45 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 122
FIG. 46 DR. REDDY'S LABORATORIES FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION) 124
FIG. 47 DR. REDDY'S LABORATORIES FINANCIAL PERFORMANCE, BY REGION (% REVENUE, 2016) 125
FIG. 48 DR. REDDY'S LABORATORIES: SWOT ANALYSIS 126
FIG. 49 ABBOTT LABORATORIES FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION) 128
FIG. 50 ABBOTT LABORATORIES: SWOT ANALYSIS 129
FIG. 51 CADILA HEALTHCARE FINANCIAL PERFORMANCE: REVENUE, 2015 - 2017 (USD MILLION) 131
FIG. 52 ACCORD HEALTHCARE INC. FINANCIAL PERFORMANCE: REVENUE, 2015 - 2017 (USD MILLION) 133
FIG. 53 PFIZER INC. FINANCIAL PERFORMANCE: REVENUE, 2014 - 2016 (USD MILLION)
Request Sample 
Request Discount 
Inquire Before Buy
